Dementia is a syndrome composed
|
|
- Bernard Hudson
- 5 years ago
- Views:
Transcription
1 Intense Focus Yet Many Setbacks for Alzheimer s Disease Drug Development Troy Kish, PharmD, BCPS Dementia is a syndrome composed of a variety of neurological deficits and impairments that affect memory, problem-solving, and/or language skills, which ultimately impact a patient s ability to function. Several forms of dementia exist, such as vascular dementia and dementia with Lewy bodies; however, Alzheimer s disease (AD) is by far the most common, accounting for 50% to 75% of cases. 1 The Centers for Disease Control and Prevention reports AD as the sixth leading cause of death and a major cause of institutionalization; 50% of all nursing home residents have AD or other forms of dementia. 2,3 With approximately 5.5 million people diagnosed in the U.S., the costs of caring for patients with AD has been estimated at $175 billion, 68% of Medicare and Medicaid s total costs. 4,5 The pathophysiology behind the development of AD is complex and still being researched. One of the leading theories centers on the accumulation of beta-amyloid (Aβ) fibrils that form plaques and lesions within the brain. Destabilization of microtubules resulting in cell death has also been attributed to the creation of neurofibrillary tangles from hyperphosphorylated tau proteins and may represent another disease pathway. Imbalances of neurotransmitters, such as glutamate, acetylcholine, serotonin, and norepinephrine, have also been demonstrated in patients with late stages of AD. Lastly, indirect inflammatory changes from the body s attempt to clear the Aβ plaques have also been suggested as a potential causative factor. 6 All of these different pathways provide a wealth of potential drug targets. Currently available treatments for AD come from two main classes of medications: acetylcholinesterase inhibitors (AChEI) and N-methyl-D-aspartate Dr. Kish is an Associate Professor of Pharmacy Practice at Long Island University, LIU Pharmacy (Arnold and Marie Schwartz College of Pharmacy and Health Sciences), in Brooklyn, New York. (NMDA) receptor antagonists. These medications focus on managing neurotransmitter imbalances and can only stabilize a patient s mental decline; they have not been shown to reverse symptoms of dementia. The role of these medications has been an area of debate given their associated costs, minimal therapeutic effects, and adverse effects, such as gastro intestinal issues, dizziness, or headache. A summary of these medications can be found in Table 1. The pharmaceutical industry has focused intensely on developing new treatments for AD, but it has been met with many setbacks over the past several years. Failures of major clinical trials have been seen with various therapeutic classes. In November 2016, Eli Lilly announced its monoclonal antibody (mab) candidate solanezumab failed to meet its primary endpoint in the large phase 3 EXPEDITION-3 trial, and the company will not pursue the drug s approval for treating. 7 Prior to that, Pfizer s bapineuzumab also failed in two phase 3 trials, which led that company to terminate all other ongoing studies. 8 In September 2017, Axovant released negative topline results from its phase 3 trial evaluating intepirdine, a small-molecule therapy, and subsequently abandoned further development of this agent. 9 This pattern highlights the complexity of this disease state, the difficulties associated with appropriate patient selection, and the appropriate timing of therapy. 10 Despite this precedent, the pipeline of medications aiming to treat AD is robust as each company hopes to be the first to bring an effective therapy to market. Clinical trials are focusing both on treating the progression of AD and managing the symptoms associated with advanced dementia, such as agitation. Medications targeting AD management can be categorized as either small-molecule drugs or as larger, protein-based therapies. The following is a discussion, in no particular order, of several upcoming medications that are in late-phase development for AD. Gantenerumab Roche has two potential biological products coming to market gantenerumab and crenezumab. Gantenerumab is a fully humanized mab that works against Aβ fibrils in the brain and facilitates their clearance through cellmediated responses. 11 Clinical findings with gantenerumab have been mixed, and the SCARLET ROAD trial, which evaluated 797 patients with prodromal AD, was discontinued due to futility in its primary endpoint of change in clinical dementia rating (CDR). However, the trial suggested potential benefit in a subgroup analysis for patients who were likely to be fast progressors and received higher doses. 12 Another phase 3 trial, MARGURITE ROAD, that was evaluating patients with mild disease has stopped recruiting patients and is continuing to monitor outcomes with no results yet reported. Based on the subgroup findings, additional phase 3 trials (GRADUATE 1 and 2) are being planned to evaluate higher doses of gantenerumab in patients with prodromal to. Treatment with gantenerumab was associated with an increase in amyloidrelated imaging abnormalities (ARIA), such as encephalopathy (ARIA-E) and hemosiderin deposition (ARIA-H). These abnormalities can be seen with all amyloid-targeting mabs. ARIA-E is associated with edema, typically developing in the parietal, occipital, or frontal lobes, which can be asymptomatic or result in confusion or altered mental status. ARIA-H is thought to come from deposits of iron in the form of hemosiderin in the brain as a result of a small leakage of blood into adjacent tissue. 13 The development of these adverse effects may present problems in future trials that are evaluating higher doses of gantenerumab because the incidence of ARIA-E appeared to be dose-dependent with rates of 0.8%, 6.6%, and 12.3% in the placebo, 105-mg, and 225-mg groups, respectively. ARIA-H occurred with a frequency of 10.9%, 19.2%, and 13.1% in 234 P&T April 2018 Vol. 43 No. 4
2 Table 1 Current FDA-Approved Medications for Alzheimer s Disease Treatment 11,37 Drug Manufacturer Aricept (donepezil) Eisai, Inc. Razadyne (galantamine) Janssen Exelon (rivastigmine) Novartis Namenda (memantine) Allergan Namzaric (memantine/donepezil) Allergan Mechanism AChEI AChEI AChEI NMDA receptor antagonist Combination AChEI and NMDA receptor antagonist Approved Use severe AD IR: mild to TD: severe AD Moderate to severe AD Moderate to severe AD Formulations Dosing AWP 37 (30-Day Supply at Maximum Dose) Brand Generic* IR: 5-mg, 10-mg, and 23-mg tablets ODT: 5-mg and 10-mg tablets IR: 4-mg, 8-mg, and 12-mg tablets ER: 8-mg, 16-mg, and 24-mg tablets OS: 4 mg/ml IR: 1.5-mg, 3-mg, 4.5-mg, and 6-mg capsules TD: 9.5-mg and 13.3-mg patches IR: 5-mg and 10-mg tablets ER: 7-mg, 14-mg, 21-mg, and 28-mg capsules OS: 2 mg/ml ER: 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, and 28 mg/10 mg capsules Mild AD: 5 10 mg Severe AD: mg IR: 8 12 mg twice daily ER: 8 24 mg OS: 8 12 mg twice daily IR: 3 6 mg twice daily TD: mg IR and OS: 10 mg twice daily ER: 28 mg 28 mg/10 mg IR: $607 ODT: N/A IR or ER: $384 OS: N/A IR: $413 TD: $777 IR: $534 ER: $509 *AWP for lowest-price generic drug at the time of writing. AChEI = acetylcholinesterase inhibitor; AD = Alzheimer s disease; AWP = average wholesale price; ER = extended release; IR = immediate release; N/A = not available; NMDA = N-methyl-D-aspartate; ODT = orally disintegrating tablet; OS = oral solution; TD = transdermal. IR: $312 ODT: $210 IR: $127 ER: $183 OS: $375 IR: $242 TD: $486 IR: $95 ER: N/A OS: OS: $635 $1,032 $507 N/A the placebo, 105-mg, and 225-mg groups, respectively. 14 Crenezumab Crenezumab is an mab with affinity for multiple aggregated forms of Aβ as well as monomers and oligomers, and it is hypothesized that crenezumab s ability to bind multiple forms of Aβ provides a lower risk for patients developing ARIA-E. Results from the phase 2 ABBY and BLAZE trials provided divergent results. ABBY evaluated 431 patients with mild-to- who received differing doses of crenezumab every two or four weeks. This trial failed to demonstrate any significant reduction in the Alzheimer s Disease Assessment Scale Cognitive 12 (ADAS cog12) or CDR Sum of Boxes (CDR SOB), which was the primary endpoint. An exploratory analysis of patients with only mild disease suggested a possible benefit in ADAS cog12 decline (35% reduction; P = 0.036) but not in CDR SOB (19% reduction; P = 0.42). 15 The BLAZE trial evaluated changes in biomarkers such as Aβ levels in the brain and cerebrospinal fluid (CSF). This trial also failed to meet its primary endpoint of Aβ levels in the brain, but was able to produce slight but significant increases in CSF concentrations, which are suggestive that crenezumab is interacting with brain plaques. 16 Initial safety data suggest crenezumab is well tolerated with no reports of ARIA-E in a dose-escalation study conducted in 52 patients. There were six cases of ARIA-H, but they did not require discontinuation of the medication. 11 Based on the data from these phase 2 trials, Roche is moving forward with two phase 3 clinical trials. CREAD1 and CREAD2 are ongoing studies of 60 mg/kg intravenous (IV) crenezumab every four weeks versus placebo to evaluate the efficacy in patients with prodromal to. The estimated completion date is 2022 for these trials. 17 It will be important to see if crenezumab is able to maintain its initial safety profile in these larger clinical trials. Aducanumab Aducanumab is a recombinant human mab derived from natural Aβ-specific antibodies. As a treatment, it is reported to bind to oligomers and insoluble fibrils of Aβ but not monomers. The ongoing phase 1b PRIME study was designed to evaluate the pharmacokinetics and pharmacodynamics of multiple doses of aducanumab while also evaluating Aβ plaque formations in the brain. Results from a 36-month follow-up were released in August 2017 that showed that amyloid plaques decreased in a time- and dosedependent manner almost to the point of nondetection as demonstrated through positron emission topography scans. Results also suggested benefit in the patients rate of decline in CDR SOB and Mini-Mental Status Exam scores. Vol. 43 No. 4 April 2018 P&T 235
3 Table 2 Therapies for Alzheimer s Disease Currently in Late-Stage Development 11 Medication Developer(s) Mechanism of Action Targeted Indication Route and Dose Gantenerumab Anti-Aβ mab Subcutaneous injection, Roche/MorphoSys dose TBD Crenezumab Roche/Genentech Aducanumab Neurimmune/ Biogen Flebogamma/ Albutein Grifols Biologicals Verubecestat Merck Elenbecestat Eisai/Biogen Lanabecestat AstraZeneca/ Eli Lilly Azeliragon vtv Therapeutics Nilvadipine Archer Pharmaceuticals Anti-Aβ mab Anti-Aβ mab IVIG albumin combination IV, 60 mg/kg or 180 mg/kg every four weeks IV, 3 mg/kg, 6 mg/kg, or 10 mg/kg every four weeks IV, with plasmapheresis, dose TBD BACE inhibitor Prodromal AD Oral, 12 mg or 40 mg BACE inhibitor BACE inhibitor Oral, 50 mg Oral, 20 mg or 50 mg Expected Price Strategy Anticipated U.S. Launch Date Priced in reference to aducanumab 2021 Priced in reference to gantenerumab 2023 Anticipated to be priced significantly above current AD therapy; likely to have first-to-market advantage Anticipated costs would be much higher than other therapies given the manufacturing process and procedures needed Expected to be priced higher than current therapies, but similar to other in-class medications Expected to be priced higher than current therapies, but similar to other in-class medications Expected to be priced higher than current therapies, but similar to other in-class medications RAGE inhibitor Mild AD Oral, 5 mg Expected to be priced at a large premium over currently available small-molecule therapies Dihydropyridine calcium-channel antagonist Oral, 8 mg Expected to be priced above current small-molecule therapies, but lower than immunotherapies AD = Alzheimer s disease; anti-aβ mab = anti-amyloid-beta monoclonal antibody; BACE = beta-secretase; IV = intravenously; IVIG = intravenous immune globulin; RAGE = receptor for advanced glycation end products; TBD = to be determined While these data are encouraging, it must be noted that these findings are based on 143 patients, and there were reports of ARIA-E in 46 patients, though this mostly did not result in discontinuation of the drug. 18 These reports have generated a lot of excitement from key opinion leaders, but some remain skeptical until further safety and cognitive efficacy data are reported. Biogen and Neurimmune are conducting two phase 3 trials, ENGAGE and EMERGE, to evaluate the role of monthly infused doses of aducanumab for the treatment of early to. Each of these trials is anticipated to evaluate 1,350 patients across 150 centers in the U.S., Europe, Australia, and Asia and to reach its primary completion date in. 19 Flebogamma/Albutein Grifols Biologicals is developing a combination product containing 5% IV immune globulin (IVIG) (Flebogamma 5% DIF) and 20% human albumin (Albutein). The rationale behind this approach stems from observational studies showing that IVIG may contain anti bodies against Aβ and thus may have a role in disease treatment or prevention. Data have been conflicting. Retrospective analyses have suggested a reduced risk of AD in patients receiving IVIG for other indications, but phase 2 or 3 trials were unable to demonstrate an impact in patients with mild-to-. 20 Reasons for these discrepancies include the various doses of IVIG studied, the timing of treatment initiation, and the formulations of IVIG used. The AMBAR trial is evaluating the role of long-term plasmapheresis with Flebogamma/Albutein following an initial plasma exchange procedure. The trial has finished enrolling patients, but preliminary results have not been released. 21 Concerns about this treatment method include the patient inconvenience of requiring regular plasmapheresis, need for specialized staff and equipment at facilities, and maintaining a sufficient supply of IVIG, a humanderived product. Verubecestat Another potential target for small molecules is the beta-secretase 1 cleaving enzyme (BACE), a key enzyme in initiating the formation of Aβ plaques in the brain. 22 Medications in this class would be used as preventive therapy for preclinical patients or for those with early stages of AD. Verubecestat is a BACE inhibitor that demonstrated the ability to produce a greater than 90% reduction of Aβ in the CSF of healthy volunteers in three phase 1 trials. Following these initial successes, Merck proceeded with two phase 3 trials, EPOCH and APECS, which evaluated patients with mild-to- and 236 P&T April 2018 Vol. 43 No. 4
4 prodromal AD, respectively. However, in February 2017, Merck terminated the EPOCH study after an interim analysis concluded there was no chance of finding a positive clinical effect. 23 The APECS trial was discontinued in February 2018 after an external data monitoring committee concluded that it was unlikely that positive benefit/risk could be established if the trial continued. 24 Lanabecestat AstraZeneca and Eli Lilly are co-developing lanabecestat, also a BACE inhibitor, for the treatment of AD. Following extensive phase 1 trials, lanabecestat was shown to reduce CSF concentrations of Aβ in a dose-dependent manner. Larger studies, such as the phase 3 DAYBREAK and phase 2/3 AMARANTH trials, are currently under way to evaluate the use of lanabecestat in patients with early AD with anticipated end dates of 2021 and 2019, respectively. 25,26 Data from phase 1 studies demonstrated a 76% or greater reduction in CSF Aβ levels following multiple doses of 50 mg daily with no major safety concerns observed in the small sample sizes. 27 Elenbecestat A third BACE inhibitor, elenbecestat, is being developed by Eisai and Biogen. Similar to the other agents in this class, elenbecestat has demonstrated the ability to substantially reduce concentrations of Aβ in the CSF and was well tolerated with only mild adverse effects of headache and dizziness. Two phase 3 trials are under way, MISSION AD1 and MISSION AD2, that are evaluating 50 mg elenbecestat in more than 1,300 patients with prodromal AD or early with a projected completion in late. 28 Future BACE Inhibitors Two additional BACE inhibitors are also in development, but on longer timelines than previously mentioned agents. Janssen and Shionogi are developing JNJ for the treatment of asymptomatic patients who are at risk of developing AD. This BACE inhibitor is being evaluated in the phase 2/3 EARLY trial, but because the primary outcome is prevention of disease, the trial will last longer than other ongoing trials and is expected to be complete in Novartis is developing CNP520 for the prevention of AD in patients determined to be high risk based on their age, apolipo protein E genotype, and presence of elevated amyloid levels. One trial, GENERATION S2, is comparing CNP520 with placebo in these high-risk patients. 30 The other trial, GENERATION S1, is being conducted in collaboration with Amgen to evaluate CNP520 and Amgen s CAD106 immunotherapy to assess the impact of these different therapies on preventing the onset of AD. It is anticipated that CNP520 would not launch until A proposed future role for the BACE inhibitor class is use in combination with immunotherapy treatments; however, large-scale clinical studies would need to be conducted to justify this therapeutic combination. Azeliragon Azeliragon (vtv Therapeutics) is in development to inhibit the receptor for advanced glycation end products (RAGE) pathway to treat AD. The stimulation of RAGE by Aβ has been observed to drive amyloid plaque formation. A phase 3, placebo-controlled trial, STEADFAST, is evaluating azeliragon 5 mg daily in combination with an AChEI with or without memantine in 800 patients with and is expected to be completed in A phase 2 trial that compared higher doses of 20 mg azeliragon per day with 5 mg per day and placebo found higher rates of confusion (8.1% versus 4.5%) and falls (10.3% versus 6.1%) as well as greater cognitive decline in the 20-mg group compared with the placebo group. 11 Nilvadipine The dihydropyridine calcium-channel blocker nilvadipine is under evaluation by Archer Pharmaceuticals. Nilvadipine helps to maintain calcium homeostasis within the brain and promotes clearance of soluble amyloid peptides to prevent their deposition into plaques. A large phase 3 trial evaluating 511 participants across nine European countries was completed in December 2016, but results are still pending publication. 33 In a small safety analysis in 86 patients with AD (56 received nilvadipine and 30 received placebo), the development of orthostatic hypotension was seen in 84% of patients in the treatment arm. 34 This safety aspect may be of concern given the increased risk of falls present in elderly patients with dementia. Intepirdine Axovant Sciences candidate intepirdine, an antagonist of serotonin receptor 6 (5-HT 6 ), was being evaluated in the treatment of mild-to- in the MINDSET study. Results from this trial showed no difference between intepirdine and placebo in the patients ADAS cog or ADAS Activities of Daily Living scores. 9 Axovant will continue to evaluate other doses of intepirdine in the treatment of other diseases, such as dementia with Lewy bodies. The outcome of the MINDSET trial was similar to previous results for other medications in this class. Idalopirdine was a candidate that produced promising phase 2 results but subsequently had negative results in three phase 3 trials. Pfizer discontinued its candidate, PF , after a phase 2 trial determined futility. 35,36 This string of failures suggests that this may not be a viable therapeutic class in AD. Older medications, such as pioglitazone and the combination of cromolyn plus ibuprofen, are being evaluated for their impact on modifying AD, but expectations are low for these therapies to have a major impact or gain much market share. 11 Other clinical trials are evaluating medications to manage symptoms associated with AD. Brexpiprazole (Rexulti, Otsuka America Pharmaceutical, Inc.) and aripiprazole are two currently approved medications being evaluated for the management of agitation in AD and would be expected to enter the market for this indication in 2018 and 2019, respectively. Novel agents for the management of agitation include Avanir/Otsuka s AVP-786, a modified formulation of the current medication dextromethorphan hydrobromide/ quinidine sulfate (Nuedexta, Avanir) and Intra-Cellular Therapies lumateperone tosylate, a 5-HT 2A receptor antagonist. 11 These therapies may prove beneficial, but they may struggle to gain market share because they would likely enter behind brexpiprazole and aripiprazole. CONCLUSION The pipeline for AD is filled with many potential candidates from varying therapeutic classes. While the prospect Vol. 43 No. 4 April 2018 P&T 237
5 of finding a viable treatment is exciting, practitioners will likely be skeptical until robust clinical trial data are available given the recent history of initial promise but ultimate disappointment with several agents. REFERENCES 1. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: Dementia and Risk Reduction An Analysis of Protective and Modifiable Factors. London, United Kingdom: Alzheimer s Disease International (ADI); Centers for Disease Control and Prevention. National vital statistics report: deaths: final data for June 30, Available at: nvsr/nvsr65/nvsr65_04.pdf. Accessed December 21, Centers for Disease Control and Prevention. Long-term care providers and services users in the United States: data from the National Study of Long-Term Care Providers, February Available at: gov/nchs/data/series/sr_03/sr03_038. pdf. Accessed December 21, Alzheimer s Association Alzheimer s disease facts and figures. Alzheimers Dement 2017;13: Alzheimer s Association. Fact sheet: costs of Alzheimer s to Medicare and Medicaid. March Available at: alz.org/site/docserver/2012_costs_ Fact_Sheet_version_2.pdf?docID=7161. Accessed December 23, Querfurth HW, LaFerla FM. Alzheimer s disease. N Engl J Med 2010;362(4): Erratum in: N Engl J Med 2011;364(6): Eli Lilly and Company. Lilly announces detailed results of solanezumab phase 3 EXPEDITION3 study at the Clinical Trials on Alzheimer s Disease (CTAD) 2016 meeting. December 8, Available at: Accessed January 12, Pfizer, Inc. Pfizer announces co-primary clinical endpoints not met in second phase 3 bapineuzumab study in mild-tomoderate Alzheimer s disease patients who do not carry the Apoe4 genotype. August 6, Available at: press.pfizer.com/press-release/pfizerannounces-co-primary-clinical-endpointsnot-met-second-phase-3-bapineuzumabstu. Accessed January 12, Axovant Sciences. Axovant announces negative topline results of intepirdine phase 3 MINDSET trial in Alzheimer s disease. September 26, Available at: Accessed January 12, Mehta D, Jackson R, Paul G, et al. Why do trials for Alzheimer s disease drugs keep failing? A discontinued drug perspective 238 P&T April 2018 Vol. 43 No. 4 for Expert Opin Investig Drugs 2017;26(6): PharmaPoint: Alzheimer s Disease Global Drug Forecast and Market Analysis to New York, New York: GlobalData; September Ostrowitzki S, Lasser R, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer s disease. Alzheimers Res Ther 2017;9(1): Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4): Lasser R, Ostrowitzki S, Scheltens P, et al. Efficacy and safety of gantenerumab in prodromal Alzheimer s disease: Results from Scarlet Road a global, multicenter trial. Alzheimers Dement 2015;11(7):P331 P Roche. Roche announces phase II clinical results of crenezumab in Alzheimer s disease. July 16, Available at: inv-update htm. Accessed January 8, Clinical Neurology News. Crenezumab posts lackluster imaging, biomarker data. November 21, Available at: www. mdedge.com/clinicalneurologynews/ article/88921/alzheimers-cognition/ crenezumab-posts-lackluster-imaging/ page/0/1. Accessed January 8, ClinicalTrials.gov. A study of crenezumab vs. placebo to evaluate the efficacy and safety in participants with prodromal to mild Alzheimer s disease. NCT October 25, Available at: clinicaltrials.gov/ct2/show/nct ?term=Crenezumab&rank=2. Accessed January 9, Biogen. Biogen reports new data from the phase 1b study of investigational Alzheimer s disease treatment aducanumab. August 28, Available at: neurodegenerative-diseases/biogenreports-new-data-phase-1b-study-investigational-alzh. Accessed January 8, ClinicalTrials.gov. Phase 3 study of aducanumab (BIIB037) in early Alzheimer s disease (EMERGE). NCT October 3, Available at: clinicaltrials.gov/ct2/show/nct ?term=Aducanumab&rank=2. Accessed January 8, Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer s disease. J Clin Immunol 2014;34(suppl 1):S74 S ClinicalTrials.gov. A study to evaluate albumin and immunoglobulin in Alzheimer s disease. NCT August 2, Available at: gov/ct2/show/nct ?term=fle bogamma&cond=alzheimer+disease&r ank=4. Accessed January 8, Vassar R. BACE1: the beta-secretase enzyme in Alzheimer s disease. J Mol Neurosci 2004;23(1 2): Merck and Co., Inc. Merck announces EPOCH study of verubecestat for the treatment of people with mild to moderate Alzheimer s disease to stop for lack of efficacy. February 14, Available at: release-details/2017/merck-announces- EPOCH-Study-of-Verubecestat-for-the- Treatment-of-People-with-Mild-to-Moderate-Alzheimers-Disease-to-Stop-for-Lackof-Efficacy. Accessed January 5, Merck and Co., Inc. Merck announces discontinuation of APECS study evaluating verubecestat (MK-8931) for the treatment of people with prodromal Alzheimer s disease. February 13, Available at: news-release/research-and-developmentnews/merck-announces-discontinuationapecs-study-evaluating-ve. Accessed February 14, ClinicalTrials.gov. A study of lanabecestat (LY ) in participants with mild Alzheimer s disease dementia (DAY- BREAK-ALZ). NCT January 9, Available at: gov/ct2/show/nct ?term=lan abecestat&rank=7. Accessed January 12, ClinicalTrials.gov. An efficacy and safety study of lanabecestat (LY ) in early Alzheimer s disease (AMARANTH). NCT January 9, Available at: NCT ?term=Lanabecestat&r ank=5. Accessed January 12, Cebers G, Alexander RC, Haeberlein SB, et al. AZD3293: pharmacokinetic and pharmaco dynamic effects in healthy subjects and patients with Alzheimer s disease. J Alzheimers Dis 2017;55(3): ClinicalTrials.gov. A 24-month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer s disease (MissionAD1). NCT December 27, Available at: elenbecestat&rank=3. Accessed January 4, ClinicalTrials.gov. An efficacy and safety study of JNJ in participants who are asymptomatic at risk for developing Alzheimer s dementia (EARLY). NCT December 15, Available at: ct2/show/nct ?term=jnj &rank=3. Accessed January 12, ClinicalTrials.gov. A study of CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer s disease (Generation S2). NCT December 5, Available at: NCT ?term=CNP520&rank=1. Accessed January 8, ClinicalTrials.gov. A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer s disease (Generation S1). NCT continued on page 248
6 continued from page 238 December 5, Available at: NCT ?term=CNP520&rank=3. Accessed January 8, ClinicalTrials.gov. Evaluation of the efficacy and safety of azeliragon (TTP488) in patients with mild Alzheimer s disease (STEADFAST). NCT June 1, Available at: gov/ct2/show/nct ?term=azeli ragon&rank=2. Accessed January 4, ClinicalTrials.gov. A phase III trial of nilvadipine to treat Alzheimer s disease (NILVAD). NCT March 6, Available at: gov/ct2/show/nct Accessed January 4, Kennelly SP, Abdullah L, Paris D, et al. Demonstration of safety in Alzheimer s patients for intervention with an antihypertensive drug nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 2011;26(10): H. Lundbeck A/S. Lundbeck annual report February 8, Available at: files.shareholder.com/downloads/amda- GGC00/ x0x926925/C05F C4E6-75BB D-53786BFBE2DD/ LUNDBECK_ANNUAL_REPORT_2016. pdf. Accessed January 4, ClinicalTrials.gov. Study evaluating the safety and efficacy of PF or placebo in subjects with Alzheimer s disease with existing neuropsychiatric symptoms on donepezil. NCT March 20, Available at: show/nct Accessed January 4, Red Book Online. Ann Arbor, Michigan: Truven Health Analytics. Accessed February 19, n 248 P&T April 2018 Vol. 43 No. 4
November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationREFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below presents the key metrics for Alzheimer s disease
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationBiogen, Cambridge, MA, USA; 2 Cytel, Cambridge, MA, USA; 3 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer s Disease Samantha Budd Haeberlein, PhD 1, Sarah Gheuens,
More informationAAIC 2018, Chicago, Illinois, US. July 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationToday s Conversation. What's New in Dementia Research and Care? Our vision is a world without Alzheimer s disease
Today s Conversation What's New in Dementia Research and Care? Heather M. Snyder, Ph.D. Medical & Scientific Relations Sam Fazio, Ph.D. Constituent Services Who We Are Alzheimer s Association International
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationCTAD 2017 Highlights, November 3-4
CTAD 2017 Highlights, November 3-4 The improved understanding of mechanisms underlying the development of AD, and thus the identification of new treatment targets, has largely been driven by genetic studies.
More informationPromising drugs in development for Alzheimer s Disease
Promising drugs in development for Alzheimer s Disease Rupert McShane Oxford Health NHS Foundation Trust University of Oxford, Department of Psychiatry Prime Ministers Challenge Diagnosis of 66% of
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAlzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
More informationDefeating Alzheimer disease and dementia when will we get the cure?
Defeating Alzheimer disease and dementia when will we get the cure? Bengt Winblad Karolinska Institutet, Dept NVS Center for Alzheimer Research Div of Neurogeriatrics Huddinge, Sweden Demensdagene Copenhagen,
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationClinical Trials Research
Clinical Trials Research Miami Campus - Dr. Marc E Agronin, Principal Investigator Name of Study: Acadia (SERENE Study) ACP-103-032 Description of Study: This is a phase II study testing to see if an investigational
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationAlzheimer Clinical Trials: History and Lessons
Alzheimer Clinical Trials: History and Lessons Jeffrey Cummings, MD, ScD Center for Neurodegeneration and Translational Neuroscience Cleveland Clinic Lou Ruvo Center for Brain Health Disclosures Dr. Cummings
More informationOutlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.
Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that
More informationA perspective on preclinical Alzheimer's disease trials
A perspective on preclinical Alzheimer's disease trials Pierre N. Tariot, MD Director, Banner Alzheimer s Institute Co-Director, API Research Professor of Psychiatry University of Arizona Disclosures I
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More information(Incidence, Treatments, Key Companies, Pipeline and Trends)
World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationAppendix 5. Characteristics of included studies. Study title: NCT
Appendix 5 Characteristics of included studies Study title: NCT00818662 Study design: 'A Randomized, Double-Blind, Placebo-led, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More informationAlzheimer s disease (AD) is the most
Therapeutic development for Alzheimer s disease at Eli Lilly and Company AUTHORS Michael Hutton 1, Michael Irizarry 2, Mark Mintun 3, Phyllis Ferrell 2, Eric Siemers 2, Christer Nordstedt 2 & Ronald DeMattos
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More information11/12/2018. Acknowledgements. Risk factors for Alzheimer s disease
Is it Possible to Reduce My Risk for Alzheimer's Disease? An Overview of Current Risk Reduction Strategies Dorothy Farrar Edwards PhD, Professor of Medicine and Kinesiology Core Leader: Outreach, Recruitment
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Efficacy and safety of amyloid-beta immunotherapy for Alzheimer's disease: systematic review Marwa El-toukhy, Mohamed Zalabia, Ahmed Raslan,
More informationAXOVANT SCIENCES LTD. JEFFERIES HEALTHCARE CONFERENCE. Axovant Sciences Corporate Presentation -- June 2017 For Investor Use Only
AXOVANT SCIENCES LTD. JEFFERIES HEALTHCARE CONFERENCE JUNE 7, 2017 FORWARD-LOOKING STATEMENTS Statements made in this presentation contain forward-looking statements, including statements regarding Axovant
More informationThe AMBAR trial: an interim analysis ASFA Annual Meeting May 6, Palm Springs. CA. Antonio Páez, MD Senior Manager, Clinical Operations Grifols
The AMBAR trial: an interim analysis ASFA Annual Meeting May 6, 206. Palm Springs. CA Antonio Páez, MD Senior Manager, Clinical Operations Grifols A multicenter, randomized, controlled study to evaluate
More informationMichael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center
Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationResearch and possible future brain health treatments
Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1 The Roskamp Institute Not for profit biomedical research
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationPharmacy Drug Class Review
April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate
More informationAlthough cholinesterase inhibitors (ChEIs) and memantine
High-dose donepezil or memantine: Next step for Alzheimer s disease? Larger dosages may benefit patients who have maxed out existing therapies Indrapal Singh, MD Assistant Professor Department of Geriatric
More informationWelcome to the Your Health Lecture Series!
Welcome to the Your Health Lecture Series! Tonight s Lecture: Alzheimer s Disease: A Look into the Future Moderator: Dr. Jean Nagelkerk Vice Provost for Health Grand Valley State University Event Begins
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationNEUROSCIENCE A Vast Unmet Need: Challenges in Alzheimer s Disease Clinical Trials
WHITE PAPER NEUROSCIENCE A Vast Unmet Need: Challenges in Alzheimer s Disease Clinical Trials ABSTRACT Despite intensive research, nearly 15 years have passed since the last new Alzheimer s disease medication
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More information42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment. Gordon K. Wilcock*, University of Oxford, UK
Efficacy and Safety of Tarenflurbil (Flurizan ), a Selective Aβ42A 42-Lowering Agent, in Alzheimer s s Disease: A Phase 2 Trial of up to 24 Months of Treatment Gordon K. Wilcock*, University of Oxford,
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationRational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia
Spectrum of AD Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia Assoc.Prof. Vorapun Senanarong, BSc., MD., DTM&H(London), FRCP(London) MCI, mild cognitive Impairment
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationTo date, all efforts to develop a disease-modifying treatment
After Disappointments, Alzheimer s Researchers Seek Out New Paths Biomarkers and Combination Therapies May Lead To Disease-Modifying Treatments, Experts Say Susan Worley John Trojanowski, MD, PhD To date,
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More information1. Developed April Revised May 2017; November 2015; March 2014; March 2012.
Texas Vendor Drug Program Drug Use Criteria: Memantine (Namenda ) Publication History 1. Developed April 2010. 2. Revised May 2017; November 2015; March 2014; March 2012. Notes: Information on indications
More informationAlzheimer s Disease Research
PRA INSIGHTS REPORT Alzheimer s Disease Research JULY 2017 Page 01 of 9 TABLE OF CONTENTS Introduction Methodology Summary Question One: Demographics Question Two: The Foremost Challenge in Neuroscience
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationPMDA Considerations for Outcome Assessments
PMDA Considerations for Outcome Assessments Keiju Motohashi Office of New Drug II Pharmaceuticals and Medical Devices Agency/ The University of Tokyo Hospital Disclaimer The views and opinions expressed
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationProthena Corporation plc Overview
November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These
More informationEARLY DEMENTIA. University of Hawaii Geriatric Medicine Department
EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT
More informationPocket Reference to Alzheimer s Disease Management
Pocket Reference to Alzheimer s Disease Management Pocket Reference to Alzheimer s Disease Management Anna Burke, MD Geriatric Psychiatrist, Dementia Specialist Geri R Hall, PhD, ARNP, GCNS, FAAN Advanced
More informationAricept, Exelon and Reminyl the new drugs for Alzheimer s disease
PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationLong-Term Care Updates
Long-Term Care Updates March 2017 By Darren Hein, PharmD Nuedexta is a fixed combination of dextromethorphan, an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist,
More informationHOMOTAURINE INVESTIGATIONAL SUMMARY
HOMOTAURINE INVESTIGATIONAL SUMMARY Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on
More informationAGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018.
AGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018. BRIEF OVERVIEW: AGITATION ASSOCIATED WITH ALZHEIMER S DISEASE (AD) AD afflicts
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationAxsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview
AXS-05 R&D Day April 24, 2018 Axsome Therapeutics, Inc. AXS-05 R&D Day CNS Pipeline Overview Herriot Tabuteau, MD Chief Executive Officer Axsome Therapeutics, Inc. New York City 3 Forward-Looking Statements
More informationAdvances in developing novel therapeutic strategies for Alzheimer s disease
Cao et al. Molecular Neurodegeneration (2018) 13:64 https://doi.org/10.1186/s13024-018-0299-8 REVIEW Advances in developing novel therapeutic strategies for Alzheimer s disease Jiqing Cao 1,2,3, Jianwei
More informationLutz Frölich 1, Glen Wunderlich 2, Claus Thamer 3, Michael Roehrle 3, Miguel Garcia Jr 4 and Bruno Dubois 5*
Frölich et al. Alzheimer's Research & Therapy (2019) 11:18 https://doi.org/10.1186/s13195-019-0467-2 RESEARCH Open Access Evaluation of the efficacy, safety and tolerability of orally administered BI 409306,
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationCognitive Decline: Memory Loss, Alzheimer s, & Dementia - Update 2018
Cognitive Decline: Memory Loss, Alzheimer s, & Dementia - Update 2018 Andrew E. Budson, M.D. Chief, Cognitive & Behavioral Neurology Veterans Affairs Boston Healthcare System Professor of Neurology, Boston
More informationActinogen Medical AGM
Actinogen Medical AGM Business Overview Dr. Bill Ketelbey: CEO & MD 28 th November 2018 Disclaimer This presentation has been prepared by Actinogen Medical Limited. ( Actinogen or the Company ) based on
More informationExploring Outcomes and Value across the Spectrum of Alzheimer s Disease Pennsylvania Avenue NW, Washington, DC June 20, 2017
Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease 1201 Pennsylvania Avenue NW, Washington, DC 20004 June 20, 2017 Meeting Summary Meeting Objectives Alzheimer s disease (AD) has a
More informationabstract n engl j med 378;4 nejm.org January 25,
The new england journal of medicine established in 1812 January 25, 2018 vol. 378 no. 4 Trial of Solanezumab for Mild Dementia Due to Alzheimer s Disease Lawrence S. Honig, M.D., Ph.D., Bruno Vellas, M.D.,
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationREFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - Executive Summary Botox: Key Metrics in the 7MM* for Migraine, 2012-2023 2012 Market Sales US $434.3m 5 EU $68.3m Japan Total
More informationPlease Join Us. International Psychogeriatric Association. Dependency Ratio. Geriatric Psychiatry in the 21st Century: A Global Perspective
International Psychogeriatric Association Please Join Us Geriatric Psychiatry in the 21st Century: A Global Perspective Jacobo Mintzer M.D. Executive Director Roper Saint Frances Clinical and Biotechnology
More informationDementia Pharmacotherapy
Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More information